TRACON Pharmaceuticals
TRACON Pharmaceuticals was a clinical-stage biopharmaceutical company that developed envafolimab, an anti-PD-L1 antibody, for sarcoma via the pivotal ENVASARC study, until stockholders approved its liquidation and dissolution in November 2024.
- Company typePublic
- Founded2006
- HeadquartersSan Diego, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
TRACON Pharmaceuticals firmographics
Firmographics- Name
- TRACON Pharmaceuticals
- Legal name
- TRACON Pharmaceuticals, Inc.
- Website
- https://traconpharma.com
- Company type
- Public
- Founded year
- 2006
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- TRACON Pharmaceuticals was a clinical-stage biopharmaceutical company that developed envafolimab, an anti-PD-L1 antibody, for sarcoma via the pivotal ENVASARC study, until stockholders approved its liquidation and dissolution in November 2024.
- Ownership category
- akta.pro rank
TRACON Pharmaceuticals industry classification
Industry- Product category
- Oncology Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
Keywords
Where TRACON Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TRACON Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
TRACON Pharmaceuticals product offering
Product offeringCore offering
TRACON Pharmaceuticals was a clinical-stage biopharmaceutical company developing targeted therapies, principally envafolimab, an anti-PD-L1 antibody, for the treatment of sarcoma through the pivotal ENVASARC study. As of November 12, 2024, stockholders voted to liquidate and dissolve the company, limiting remaining activity to winding up business affairs.
Differentiator
Problem solved
Functional benefit
Products and services
- Envafolimab
Companies that use TRACON Pharmaceuticals
Customer profileIdeal customer profiles2 records
TRACON Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
TRACON Pharmaceuticals partnerships and signals
Strategic signalScale indicators3 records
TRACON Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- CytRx Corporation: CytRx was a small clinical-stage biopharmaceutical company with a sarcoma-focused pipeline. Highly comparable to TRACON given overlapping therapeutic focus (soft tissue sarcoma) and similar small-cap, single-asset clinical development profile.
- Aadi Bioscience: Aadi Bioscience is a clinical-stage biopharmaceutical company focused on treating patients with rare oncology indications including sarcoma. Directly comparable in therapeutic area and small clinical-stage operating model.
- Infinity Pharmaceuticals: Infinity is a clinical-stage oncology company developing immuno-oncology and related therapies. Comparable in size, business model, and clinical-development-stage focus on cancer therapeutics.
- Checkpoint Therapeutics: Checkpoint Therapeutics is a clinical-stage immuno-oncology company developing PD-L1 and other checkpoint-based therapies. Directly comparable as a small-cap developer of PD-L1 antibodies for oncology.
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based immuno-oncology therapeutics. Comparable in technology platform (antibody-based oncology), although at a larger scale.
- NewLink Genetics: NewLink Genetics is a clinical-stage immuno-oncology company. Highly comparable in therapeutic area and clinical-stage, small-cap development profile.
Broad incumbents
- AstraZeneca: AstraZeneca markets Imfinzi (durvalumab), an approved anti-PD-L1 antibody in immuno-oncology. Relevant as a broad incumbent in the PD-L1/immuno-oncology space where TRACON's envafolimab competed.
- Roche (Genentech): Roche/Genentech markets Tecentriq (atezolizumab), an approved anti-PD-L1 antibody. Broad incumbent competitor in the same drug class as TRACON's envafolimab.
- Merck & Co. Merck markets Keytruda (pembrolizumab), the dominant PD-1 inhibitor and the benchmark immuno-oncology therapy. Represents the entrenched competitor whose commercial dominance framed TRACON's clinical opportunity.
- Bristol-Myers Squibb: BMS markets Opdivo (nivolumab), a leading PD-1 checkpoint inhibitor. Broad incumbent in the immuno-oncology class relevant to envafolimab's mechanism of action.
Market position
Customer concentration
TRACON Pharmaceuticals social profiles
Digital presenceTRACON Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
TRACON Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles4 records
TRACON Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds10 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TRACON Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TRACON Pharmaceuticals
What does TRACON Pharmaceuticals do?
TRACON Pharmaceuticals was a clinical-stage biopharmaceutical company developing targeted therapies, principally envafolimab, an anti-PD-L1 antibody, for the treatment of sarcoma through the pivotal ENVASARC study. As of November 12, 2024, stockholders voted to liquidate and dissolve the company, limiting remaining activity to winding up business affairs.
Is TRACON Pharmaceuticals a public or private company?
TRACON Pharmaceuticals is a public company. It is classified as public and is currently closed.
When was TRACON Pharmaceuticals founded?
TRACON Pharmaceuticals was founded in 2006. It employs 11 to 50 people.
Where is TRACON Pharmaceuticals based?
TRACON Pharmaceuticals is headquartered in San Diego, United States, in the North America region.
Who are TRACON Pharmaceuticals's main competitors?
Direct peers on record are CytRx Corporation, Aadi Bioscience, Infinity Pharmaceuticals, Checkpoint Therapeutics, MacroGenics and NewLink Genetics. Broad incumbents are AstraZeneca, Roche (Genentech), Merck & Co. and Bristol-Myers Squibb.
Does TRACON Pharmaceuticals have an API?
No public API is recorded for TRACON Pharmaceuticals.
What industry is TRACON Pharmaceuticals in?
TRACON Pharmaceuticals's product category is Oncology Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 325412 and its SIC code is 2834.